TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14510719
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (400 microg bid)
Study: 14510719
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (200 microg bid)
Study: 6220672
Drug: Norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 200 mg
Study: 6220672
Drug: Norfloxacin 800
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 800 mg
Study: 6220672
Drug: Norfloxacin 1200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 1200 mg
Study: 6220672
Drug: Norfloxacin 1600
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 1600 mg
Study: 30072173
Drug: Music Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Group (daily listening to experiential/traditional music)
Study: 30072173
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (standard care only, no music therapy)
Study: 26911380
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (300 mg/day)
Study: 12560588
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-drug)
Study: 10138581
Drug: Intervention phase
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention phase with dosage interval adjustment recommendations by staff pharmacists
Study: 10138581
Drug: Baseline phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline phase without dosage interval adjustment
Study: 998534
Drug: Saturated diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated diet with added cholesterol (291 mg)
Study: 998534
Drug: Polyunsaturated diet
Normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated diet with added cholesterol (291 mg)
Study: 27681865
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (cCRTX)
Study: 10994885
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) at a dose of 0.1 mg/kg for 29 days
Study: 8851268
Drug: Taprostene administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taprostene administered as a continuous intravenous infusion from 2 hours before until 8 or 24 hours after angioplasty.
Study: 8851268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a combination of 330 mg aspirin and 75 mg dipyridamole.
Study: 8851268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (aspirin and dipyridamole).
Study: 10147024
Drug: Aminoglycoside/antianaerobe combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside/antianaerobe combination regimens
Study: 6337200
Drug: Aspirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (10 gr twice daily)
Study: 29651981
Drug: Lamotrigine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (up to 200 mg/day, or up to 400 mg/day for women on combined oral contraceptives)
Study: 24739593
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin (combination therapy)
Study: 19837920
Drug: ID fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID fat infusion with orlistat
Study: 16270634
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human FXIII A2 (rFXIII) at doses of 10 or 25 U/kg
Study: 11801583
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) 4 mg/kg/day
Study: 7754475
Drug: Minocycline (Mynocine)
Normalized name: minocycline Injection [Minocin]
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline (Mynocine) 100 mg per day
Study: 7754475
Drug: Roxithromycin (Rulid)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (Rulid) 300 mg per day
Study: 2407004
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) at various dosages (40 mg/m2, 80 mg/m2, 120 mg/m2, 180 mg/m2, 220 mg/m2)
Study: 2407004
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of 15-deoxyspergualin (DSG) with other agents
Study: 30655198
Drug: Succinylcholine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (group SUX) for intubation with no further NMB administered
Study: 26717354
Drug: Sargassum extract
Normalized name: Sargassum pallidum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sargassum extract 250 μg/mL
Study: 26717354
Drug: Sargassum extract
Normalized name: Sargassum pallidum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sargassum extract 500 μg/mL
Study: 19639620
Drug: 1,550 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,550 nm Er:Glass fractional laser (3 treatments with 6-week intervals)
Study: 19639620
Drug: CROSS method
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CROSS method (2 treatments every 12 weeks)
Study: 10543411
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg glimepiride
Study: 11903417
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glimepiride
Study: 8432776
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alpha human atrial natriuretic peptide (ANP) infusion (2.5 pmol/kg.min)
Study: 27426932
Drug: 7.44 mg
Normalized name: aluminum sulfate 7.44 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.44 mg total macular carotenoid
Study: 27426932
Drug: 13.13 mg
Normalized name: DIMETHICONE 13.13 mg in 1 mL TOPICAL LOTION [Daily Moisturizing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.13 mg total macular carotenoid
Study: 27426932
Drug: 27.03 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27.03 mg total macular carotenoid
Study: 16622454
Drug: Docetaxel 80
Normalized name: DOCETAXEL 80MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 80 mg m‐2 and epirubicin 75 mg m‐2 (ED)
Study: 16622454
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg m‐2 (D)
Study: 11763004
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg daily for 6 weeks)
Study: 8989002
Drug: Propofol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.1 mg/kg bolus followed by 1 mg.kg-1.h-1 continuous infusion)
Study: 31538405
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injection of 1 mL 0.5% bupivacaine with 3 cycles of pulsed radiofrequency of the DRG for 180 seconds (LPRF group)
Study: 31538405
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injection of 1 mL 0.5% bupivacaine (LA group)
Study: 29309313
Drug: Automated mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated mechanical peripheral stimulation (AMPS) applied twice a week for 4 weeks using a commercial medical device (Gondola) delivering mechanical pressure in four areas of feet.
Study: 29309313
Drug: AMPS SHAM
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPS SHAM (placebo) applied twice a week for 4 weeks delivering subliminal stimulus.
Study: 26343552
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with adjunctive use of an essential-oil (EO)-based oral rinse for 30 days
Study: 9369828
Drug: Single-dose cefotetan
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefotetan (2 gm intravenous)
Study: 9369828
Drug: Multiple-dose cefotetan
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose cefotetan (2 gm intravenous every 12 hours for a minimum of 48 hours)
Study: 9369828
Drug: Single-dose cefotetan
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefotetan
Study: 9369828
Drug: Multiple-dose cefotetan
Normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose cefotetan
Study: 30962409
Drug: HL301 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL301 (600 mg/day)
Study: 31855086
Drug: Umckamin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umckamin (333 mg/day)
Study: 31720257
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (13.5 g Hi-Maize 260 daily for 4 weeks)
Study: 21411598
Drug: Control (EPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (EPI vaccines alone)
Study: 15988081
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Depakin (30 mg/kg) and Mexidol (5 mg/kg) in children with generalized epilepsy.
Study: 15988081
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with Mexidol (5 mg/kg) in children with first episode of febrile seizures.
Study: 15988081
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without any treatment in children with first episode of febrile seizures.
Study: 10491894
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole 10 mg every 8 hours
Study: 10491894
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin 300 mg every 24 hours
Study: 8708728
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (DaunoXome) 40 mg/m2
Study: 6753911
Drug: Captopril 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 37.5 mg, 75 mg or 150 mg/day for 7 weeks
Study: 6753911
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus hydrochlorothiazide 25 mg twice daily
Study: 30877851
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with D-cycloserine augmentation
Study: 30877851
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with placebo augmentation
Study: 28712074
Drug: 12.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/day SHP465 MAS
Study: 28712074
Drug: 37.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg/day SHP465 MAS
Study: 26825824
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose oral cyclophosphamide 50 mg and methotrexate 2.5 mg (maintenance arm)
Study: 24956453
Drug: GA with
Normalized name: Tums with Gas Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA with a single‐injection TPVB and placebo paravertebral infusion
Study: 22103956
Drug: Low-dosage control
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage control group workshop
Study: 19924281
Drug: RTS,S/AS vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS vaccines (pooled)
Study: 11581040
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia without intravenous sedatives
Study: 11581040
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia without intravenous sedatives
Study: 11581040
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with intravenous sedatives
Study: 11581040
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia with intravenous sedatives
Study: 11581040
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia with short-acting hypnotic agents (alone)
Study: 11581040
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia with short-acting hypnotic agents (with opiates)
Study: 11581040
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia with short-acting hypnotic agents (with sedatives)
Study: 11581040
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia with short-acting hypnotic agents (with opiates and sedatives)
Study: 9636865
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (100 mg once daily for 14 days)
Study: 9636865
Drug: Fluconazole capsules
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole capsules (100 mg once daily for 14 days)
Study: 9636865
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (100 mg twice daily for 7 days)
Study: 3276670
Drug: Desipramine in
Normalized name: desipramine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine in combination with methadone
Study: 25661282
Drug: suvorexant (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant (40 mg in <65 y-olds; 30 mg in ≥65 y-olds)
Study: 18652757
Drug: V80/H12.5 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: V80/H12.5 (80 mg valsartan/12.5 mg hydrochlorothiazide)
Study: 18652757
Drug: V80 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: V80 (80 mg valsartan)
Study: 12664247
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral diazepam (Dz)
Study: 10560170
Drug: Over-the-counter (OTC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter (OTC) use of nicotine replacement therapy
Study: 10560170
Drug: Medical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical prescription of nicotine substitutes
Study: 2071269
Drug: Voltaren 'A'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren 'A' (50 mg)
Study: 2071269
Drug: Inflaban 'B'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflaban 'B' (50 mg)
Study: 6353620
Drug: Intravenous domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous domperidone 10 mg
Study: 23386645
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D2 daily for 11 weeks
Study: 23386645
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D3 daily for 11 weeks
Study: 17127226
Drug: Levofloxacin 250
Normalized name: levofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 250 mg oral, once daily (LVFX)
Study: 17127226
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg oral, twice daily (CPFX)
Study: 17127226
Drug: Placebo one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet oral once daily (P group)
Study: 15023707
Drug: Mupirocin 2%
Normalized name: MUPIROCIN 2% OINT
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin 2% nasal ointment (n = 793)
Study: 15023707
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (n = 809)
Study: 27163519
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.45 or 0.625 mg/Bazedoxifene (BZA) 20 mg
Study: 21459785
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium concentration of 1.12 mmol/L
Study: 21459785
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium concentration of 1.37 mmol/L
Study: 18089701
Drug: Calcium 1200
Normalized name: Premier Value Calcium 1200 + D3 Extended-Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1200 mg/d with placebo vitamin D (Ca group)
Study: 18089701
Drug: Calcium 1200
Normalized name: Premier Value Calcium 1200 + D3 Extended-Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1200 mg/d with 1000 IU/d vitamin D2 (CaD group)
Study: 12906343
Drug: Selenium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium therapy (200 microg/day)
Study: 10715288
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 175 mg/m(2) over 3 hours every 3 weeks
Study: 10715288
Drug: Oxaliplatin at
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin at 130 mg/m(2) over 2 hours every 3 weeks
Study: 1528969
Drug: Continuous venotonic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venotonic treatment for one month
Study: 1528969
Drug: Intermittent venotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent venotonic treatment in parallel with active contraceptive treatment from the 10th to the 28th day
Study: 7449633
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide dinitrate (10 subjects)
Study: 7449633
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg prazosin (20 subjects)
Study: 7449633
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dihydralazine (8 subjects)
Study: 31141099
Drug: Low socioeconomic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low socioeconomic status (L-SES)
Study: 27916286
Drug: Relating Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relating Therapy (RT)
Study: 23567399
Drug: Peaceful Mind
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peaceful Mind intervention (up to 12 weekly in-home sessions and up to eight brief telephone sessions)
Study: 22176903
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (5 mg) for 12 weeks
Study: 19475468
Drug: Bilateral infraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral infraorbital injections with 0.5% bupivacaine (Group IOB)
Study: 14597937
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (conjugated estrogens and medroxyprogesterone)
Study: 10400007
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + Aspirin
Study: 7271091
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg once daily for 7 days
Study: 7271091
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg once daily for 21 days
Study: 31201476
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor agonist, pramipexole 0.5 mg
Study: 31201476
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor antagonist, amisulpride 400 mg
Study: 18443258
Drug: ACEIs or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEIs or angiotensin receptor blockers
Study: 8844718
Drug: Fructo-oligosaccharides (FOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (FOS) 12.5 g/day
Study: 1739571
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg kg‐1 with adrenaline 1 in 200,000 plus hyaluronidase 3000 iu
Study: 1739571
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg kg‐1 with adrenaline 1 in 200,000 without hyaluronidase
Study: 6371788
Drug: Zaditen syrup
Normalized name: Zaditen
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zaditen syrup
Study: 24561494
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daily pravastatin
Study: 22322521
Drug: Articaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine (40 mg with Epinephrine 0.5 mg %)
Study: 22322521
Drug: Articaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine (40 mg with Epinephrine 1 mg %)
Study: 22322521
Drug: Mepivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (30 mg with Epinephrine 1 mg %)
Study: 22322521
Drug: Mepivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (20 mg with Epinephrine 1 mg %)
Study: 20850004
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate 2·4 mg/kg at 0, 12, and 24 hours, then daily